Tropical diseases (e.g., dengue) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Tropical diseases are infections that thrive in warm, humid climates—typically found in regions between the Tropic of Cancer and the Tropic of Capricorn. While there are hundreds of agents (viruses, bacteria, parasites, fungi), this guide focuses on dengue fever, the most prevalent mosquito‑borne viral disease worldwide.

Who it affects: Anyone living in or traveling to endemic areas can be infected, but children, the elderly, and people with weakened immune systems are at higher risk of severe disease.

Global prevalence (2022 data):

• World Health Organization (WHO) estimates ~390 million dengue infections per year, of which ~96 million manifest clinically.
• Over 3 billion people—about 40 % of the world’s population—live in areas at risk for dengue transmission.
• The Americas, Southeast Asia, and the Western Pacific account for >75 % of reported cases.

Symptoms

Dengue presents a broad spectrum, from asymptomatic infection to life‑threatening dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Symptoms typically appear 4–10 days after the bite of an infected Aedes mosquito.

Typical (mild to moderate) dengue

• High fever – sudden onset, often 40 °C (104 °F) or higher, lasting 2–7 days.
• Severe headache – especially behind the eyes (retro‑orbital pain).
• Muscle and joint pain – “break‑bone fever” because pain can be intense.
• Fatigue and malaise – may last weeks after fever subsides.
• Skin rash – pink to red maculopapular rash that may appear 3–5 days after fever onset.
• Nausea, vomiting, or abdominal discomfort.
• Low platelet count (thrombocytopenia) – detectable on blood tests, may cause easy bruising.

Severe dengue (DHF/DSS)

• Persistent vomiting or severe abdominal pain.
• Rapid drop in platelet count (<100,000/µL) and hematocrit rise >20 % (sign of plasma leakage).
• Bleeding gums, nosebleeds, or easy bruising.
• Difficulty breathing, cold or clammy skin, weak pulse – signs of shock.
• Organ involvement (liver enlargement, elevated transaminases, encephalopathy).

Causes and Risk Factors

What causes dengue?

Dengue is caused by four closely related viruses (DENV‑1, DENV‑2, DENV‑3, DENV‑4) transmitted primarily by the daytime‑biting Aedes aegypti mosquito and, to a lesser extent, Aedes albopictus. The virus replicates in human skin cells, spreads to lymph nodes, and then circulates in the bloodstream.

Key risk factors

• Geography: Living in or traveling to endemic tropical/subtropical regions.
• Urbanization: Dense housing with poor water storage creates breeding sites.
• Climate: Warm temperatures and rainy seasons boost mosquito populations.
• Previous infection: A secondary infection with a different serotype increases risk of severe dengue due to antibody‑dependent enhancement.
• Age: Children <5 years and adults >65 years are more prone to severe disease.
• Pregnancy: May increase risk of complications for both mother and fetus.

Diagnosis

Early and accurate diagnosis guides proper monitoring and fluid management, which are crucial for preventing severe outcomes.

Clinical assessment

• History of recent travel or residence in endemic area.
• Sudden high fever with characteristic symptoms.

Laboratory tests

• NS1 antigen test – Detects dengue virus NS1 protein from day 1 to day 7 of illness; rapid (15‑30 min) and highly specific (≈95 %).
• Reverse transcription polymerase chain reaction (RT‑PCR) – Detects viral RNA; useful during the first 5 days, informs serotype.
• IgM/IgG serology – IgM appears ~5 days after onset; IgG rises later and indicates past infection or secondary exposure.
• Complete blood count (CBC) – Looks for thrombocytopenia, leukopenia, and hematocrit rise (plasma leakage).
• Liver function tests – Elevated ALT/AST are common.

Reference: WHO Dengue Guidelines 2022; CDC “Dengue Laboratory Testing” [1].

Treatment Options

There is no specific antiviral therapy for dengue; treatment is supportive and focuses on maintaining fluid balance and monitoring for complications.

Acute phase (days 1‑7)

• Hydration – Oral rehydration solutions (ORS) or intravenous (IV) crystalloid fluids (e.g., normal saline) if oral intake is insufficient or warning signs appear.
• Fever & pain control – Acetaminophen (paracetamol) 500‑1000 mg every 6 h (max 4 g/day). Avoid NSAIDs (ibuprofen, aspirin) as they increase bleeding risk.
• Monitoring – Daily CBC, hematocrit, and clinical assessment for signs of plasma leakage.

Severe dengue

• IV fluid resuscitation with isotonic solutions; guided by hematocrit and urine output.
• Blood component therapy (platelet transfusion, packed red cells) if active bleeding or dangerously low platelet counts (<20,000/µL) combined with hemorrhage.
• Intensive‑care support for shock, respiratory distress, or organ failure.

Emerging therapies

• Dengvaxia (CYD‑TDV) – A live‑attenuated tetravalent vaccine approved in several countries; recommended only for individuals with documented prior dengue infection due to risk of severe disease in seronegative recipients.
• Clinical trials are evaluating monoclonal antibodies (e.g., tafamidis) and antiviral candidates (e.g., balapiravir).

Living with Tropical Diseases (e.g., Dengue)

Even after recovery, patients may experience lingering fatigue, mood changes, or joint pain for weeks to months (“post‑dengue syndrome”). Practical tips:

• Stay hydrated – Continue drinking water, electrolyte drinks, and soups.
• Gradual return to activity – Begin with light walking; avoid strenuous exercise for at least 2 weeks.
• Nutrition – Eat a balanced diet rich in fruits, vegetables, and lean protein to support immune recovery.
• Monitor platelet trends – If you have ongoing low platelets, schedule follow‑up CBCs.
• Psychological health – Persistent fatigue can affect mood; seek counseling or support groups if needed.
• Vaccination counseling – Discuss eligibility for Dengvaxia or emerging vaccines with your physician.

Prevention

Because dengue has no cure, preventing mosquito bites is the cornerstone of control.

Personal protective measures

• Use EPA‑registered insect repellents containing DEET (≤30 %), picaridin, IR3535, or oil of lemon eucalyptus.
• Wear long‑sleeved shirts and long pants, especially during daylight hours (peak Aedes activity).
• Sleep under mosquito‑netting (treated with permethrin) when in poorly screened accommodation.
• Apply larvicides (e.g., Bacillus thuringiensis israelensis) to water containers that cannot be emptied.

Environmental control

• Eliminate standing water: empty, clean, or cover buckets, flower pots, tires, and gutters weekly.
• Use community‑wide source reduction campaigns; many cities in Brazil and Singapore have achieved >80 % reduction in breeding sites.
• Introduce biological control agents such as Wolbachia-infected mosquitoes, which reduce virus transmission.

Vaccination

For individuals 9–45 years old with documented prior infection, a three‑dose series of Dengvaxia (0, 6, 12 months) confers ~60‑70 % protection against hospitalization. Discuss eligibility with a healthcare provider.

Complications

If dengue is not recognized or managed promptly, several serious complications can arise:

• Dengue hemorrhagic fever (DHF) – Vascular leakage leading to hemoconcentration, pleural effusion, and ascites.
• Dengue shock syndrome (DSS) – Severe plasma loss causing hypotension, organ hypoperfusion, and death if untreated.
• Severe organ involvement – Hepatitis, myocarditis, encephalitis, or acute kidney injury.
• Secondary bacterial infection – Due to gut permeability changes.
• Pregnancy complications – Preterm birth, low birth weight, or miscarriage.

When to Seek Emergency Care

---

Sources:

1. World Health Organization. Dengue Guidelines, 2022. doi:10.2471/BLT.09.067949
2. Centers for Disease Control and Prevention. Dengue Virus: Laboratory Testing. cdc.gov
3. Mayo Clinic. Dengue Fever. mayoclinic.org
4. Cleveland Clinic. Dengue Fever: Symptoms and Treatment. clevelandclinic.org
5. National Institutes of Health. Dengue Vaccine Development. nih.gov

```